One of the research team and University of Otago chemistry professor Lyall Hanton said the company aimed to capture 20-30% of the US market by the end of 2020. The gel, developed by NZ medical science company Chitogel and involving University of Otago scientists, will be used after endoscopic sinus surgery to reduce bleeding and almost entirely eliminate scarring. Those post-operative complications lead to about 15% of the operations being repeated but the gel could significantly reduce that. Endoscopic sinus surgery is one of the most common surgical procedures performed with more than 500,000 carried out each year in the US alone. "I am delighted that something we have worked so long and hard on, is finally able to make a fundamental difference to people recovering from this type of sinus surgery.

Source: Otago Daily Times November 08, 2017 00:33 UTC